Urate and neuroprotection trials

The Lancet Neurology

Volumn 13, Issue 8, 2014, Pages 758-

  Schwarzschild, Michael A ^a   Macklin, Eric A ^a   Ascherio, Alberto ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

URATE; ANTIOXIDANT; URIC ACID; INOSINE; PLACEBO;

CEREBROVASCULAR ACCIDENT; HUMAN; LETTER; NEUROPROTECTION; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SEX DIFFERENCE; UNIFIED PARKINSON DISEASE RATING SCALE; URIC ACID BLOOD LEVEL; FEMALE; MALE; NOTE; CEREBROSPINAL FLUID; CHAMORRO (PEOPLE); DRUG SAFETY; DRUG TOLERABILITY; SECONDARY ANALYSIS;

ANTIOXIDANTS; FEMALE; HUMANS; MALE; STROKE; URIC ACID;

EID: 84904266923     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70138-3     Document Type: Letter

References (5)

1. Chamorro A, Amaro S, Castellanos M, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol 2014, 13:453-460.
2. Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009, 66:1460-1468.
3. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014, 71:141-150. The Parkinson Study Group SURE-PD Investigators.
4. Abraham A, Drory VE Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol 2014, published online April 4. http://dx.doi.org/10.1007/s00415-014-7331-x.
5. Chen X, Wu G, Schwarzschild MA Urate in Parkinson's disease: more than a biomarker?. Curr Neurol Neurosci Rep 2012, 12:367-375.